84
Participants
Start Date
March 17, 2025
Primary Completion Date
November 1, 2025
Study Completion Date
September 1, 2026
Recombinant LH (Luveris)
In the treatment group patients will receive the pretreatment with rLH, a daily dose of 187.5 IU (75 U in the morning and 112.5U in the evening) rLH treatment for 60 days will be administered.
No Treatment Added
In the control group, women will not receive any therapy and will be followed up with the same schedule as women in the treatment group
Azienda Ospedaliero-Universitaria di Modena
OTHER